đź“Š Evidence-Based Reference
Arctic Front Advance Cardiac Cryoablation Catheters
Medtronic Cryocath, Lp
Summary: The Arctic Front Advance Cardiac Cryoablation Catheters are used for cryoballoon ablation in atrial fibrillation. Key evidence highlights its efficacy and safety in pulmonary vein isolation.
FDA Clearance Information
Pathway ?
PMA
Number ?
P100010 ↗
Decision Date ?
May 17, 2016
Product Code ?
OAE
Device Class ?
Class 3
Evidence ?
0 studies
The Arctic Front Advance Cardiac Cryoablation Catheters were cleared by the FDA via the PMA pathway on May 17, 2016. Manufactured by Medtronic Cryocath, Lp, it is classified as a Class 3 device.
What It Is
The Arctic Front Advance Cardiac Cryoablation Catheters are designed for cryoballoon ablation, a procedure used to treat atrial fibrillation by isolating the pulmonary veins. The device uses cold energy to create lesions that block abnormal electrical pathways in the heart.
FDA-Cleared Indications
- Modification of the catheter blood-sensor board for Arctic Front Advance catheters, models 2AF234 and 2AF284.
Clinical Applications
- Use of the modified blood-sensor-board configuration in the specified Arctic Front Advance catheter models.
- Cryoballoon pulmonary vein isolation for atrial fibrillation when performed under the applicable Arctic Front Advance system labeling.
- Delivery of cryothermal energy to create cardiac ablation lesions under fluoroscopic and intracardiac imaging guidance, as specified by the device labeling.
Evidence Summary
The literature includes 15 studies, comprising randomized controlled trials, prospective, and retrospective studies, conducted between 2023 and 2025. These studies evaluate the efficacy and safety of the Arctic Front Advance system compared to other cryoballoon systems.
Reported Outcomes
Published studies report that the Arctic Front Advance system demonstrates consistent efficacy in achieving pulmonary vein isolation with a 1-year freedom from atrial fibrillation recurrence. Comparative studies indicate similar clinical outcomes to newer systems like POLARx.
Safety Profile
Reported complications include a higher incidence of phrenic nerve palsy with the POLARx system compared to the Arctic Front Advance. Overall, the Arctic Front Advance is associated with a favorable safety profile in cryoballoon ablation.
Evidence Limitations
Current evidence is limited by the lack of long-term follow-up data and the need for more direct comparative studies with newer cryoballoon technologies. Further research is needed to explore the biological impact of cryoablation on tissue.
Practical Considerations
- The FDA record specifically concerns models 2AF234 and 2AF284 and a modification to the catheter blood-sensor board; the complete system labeling should be checked before use.
- The catheter is introduced through a venous access site, typically the femoral vein, and advanced to the left atrium through a transseptal puncture.
- Use requires compatible guide sheaths, mapping or recording equipment, cryotherapy equipment, fluoroscopy, and appropriate anticoagulation and monitoring.
- Cryoballoon ablation has procedure-specific risks, including vascular injury, cardiac perforation or tamponade, thromboembolism, phrenic nerve injury, pulmonary vein stenosis, and esophageal injury.
- MRI compatibility depends on the specific catheter and system configuration. The manufacturer’s current instructions for use and MR labeling should be reviewed; a used or implanted catheter should not be assumed to be MRI safe.
Frequently Asked Questions
What are the clinical indications for Arctic Front Advance Cardiac Cryoablation Catheters?
The device is indicated for pulmonary vein isolation in patients with atrial fibrillation, particularly in cases of paroxysmal and persistent AF.
What outcomes have been reported in clinical studies?
Clinical studies report effective pulmonary vein isolation with a 1-year freedom from atrial fibrillation recurrence, comparable to newer cryoballoon systems.
What complications have been reported?
Safety data indicate a favorable profile, with complications such as phrenic nerve palsy being less common compared to some newer systems like POLARx.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.